Evidence map›Paper›PMID 37204562›Full record

ReviewCancer metastasis reviews2023

Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics.

Archana Sharma, Diksha Sharma, Neha Saini, Sunil V Sharma, Vijay Kumar Thakur, Ramesh K Goyal, Prabodh Chander Sharma

Open access · hybridAbstract readReview
In one paragraph

Review in Cancer metastasis reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. d‑Glucose-Conjugated Benzo[ACS medicinal chemistry letters · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Archana SharmaDIPSAR, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India.
Diksha SharmaSwami Devi Dayal College of Pharmacy, Barwala, 134118, India.
Neha SainiSwami Devi Dayal College of Pharmacy, Barwala, 134118, India.
Sunil V SharmaSchool of Chemistry, North Haugh, University of St Andrews, St Andrews, Fife, 16 9ST, KYScotland, UK.
Vijay Kumar ThakurBiorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), King's Buildings, West Mains Road, Edinburgh, EH9 3JG, UK. vijay.thakur@sruc.ac.uk.ORCID 0000-0002-0790-2264
Ramesh K GoyalSPS, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India.
Prabodh Chander SharmaSPS, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India. sharma.prabodh@dpsru.edu.in.
Delhi Pharmaceutical Science and Research University · INSwami Devi Dyal Hospital and Dental College · INScotland's Rural College · GBUniversity of St Andrews · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the life-threatening diseases accountable for millions of demises globally. The inadequate effectiveness of the existing chemotherapy and its harmful effects has resulted in the necessity of developing innovative anticancer agents. Thiazolidin-4-one scaffold is among the most important chemical skeletons that illustrate anticancer activity. Thiazolidin-4-one derivatives have been the subject of extensive research and current scientific literature reveals that these compounds have shown significant anticancer activities. This manuscript is an earnest attempt to review novel thiazolidin-4-one derivatives demonstrating considerable potential as anticancer agents along with a brief discussion of medicinal chemistry-related aspects of these compounds and structural activity relationship studies in order to develop possible multi-target enzyme inhibitors. Most recently, various synthetic strategies have been developed by researchers to get various thiazolidin-4-one derivatives. In this review, the authors highlight the various synthetic, green, and nanomaterial-based synthesis routes of thiazolidin-4-ones as well as their role in anticancer activity by inhibition of various enzymes and cell lines. The detailed description of the existing modern standards in the field presented in this article may be interesting and beneficial to the scientists for further exploration of these heterocyclic compounds as possible anticancer agents.

Indexed as

Antineoplastic AgentsNeoplasmsHumansStructure-Activity RelationshipAntineoplastic AgentsAnticancerAnti-proliferativeAnti-tumorCell linesCytotoxicSynthesisThiazolidin-4-one

Identifiers

PMID37204562
PMCPMC10584807
OpenAlexW4377094265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.